Tenofovir (TDF) and Emtricitabine (FTC)
Phase 1/2Withdrawn 0 watching 0 views this week⚡ Active
40
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Aicardi Goutières Syndrome
Conditions
Aicardi Goutières Syndrome
Trial Timeline
Dec 1, 2025 → Dec 1, 2029
NCT ID
NCT03304717About Tenofovir (TDF) and Emtricitabine (FTC)
Tenofovir (TDF) and Emtricitabine (FTC) is a phase 1/2 stage product being developed by Gilead Sciences for Aicardi Goutières Syndrome. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03304717. Target conditions include Aicardi Goutières Syndrome.
Hype Score Breakdown
Clinical
13
Activity
8
Company
9
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03304717 | Phase 1/2 | Withdrawn |
Competing Products
1 competing product in Aicardi Goutières Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Baricitinib | Eli Lilly | Phase 2 | 52 |